Understanding the Risks of CBD Products
CBD products are widely available. Yet, our scientific understanding of their benefits and possible adverse health effects has not kept pace with the production and use of these products. To compound this problem, state and federal regulators have yet to enact consistent guidance on how CBD products may be manufactured, how CBD products are marketed, or what, if any, warnings are necessary to provide to consumers. This article provides a quick overview of CBD, THC, and other cannabinoids and the growing availability of CBD-containing products along with the lack of state and federal regulation and risk information, discusses potential exposure levels associated with various CBD products and compares them to a federally-regulated pharmaceutical. It also highlights repercussions of THC’s listing on California’s Proposition 65 that took effect January 3, 2021.
Read the article on Gradient’s website.
Authors:
Tom A. Lewandowski, Ph.D., DABT, ERT, ATS
Principal
tlewandowski@gradientcorp.com
James W. Rice, Ph.D.
Senior Environmental Scientist
jrice@gradientcorp.com
